Your browser doesn't support javascript.
loading
Schwannomatosis: a genetic and epidemiological study.
Evans, D Gareth; Bowers, Naomi L; Tobi, Simon; Hartley, Claire; Wallace, Andrew J; King, Andrew T; Lloyd, Simon K W; Rutherford, Scott A; Hammerbeck-Ward, Charlotte; Pathmanaban, Omar N; Freeman, Simon R; Ealing, John; Kellett, Mark; Laitt, Roger; Thomas, Owen; Halliday, Dorothy; Ferner, Rosalie; Taylor, Amy; Duff, Chris; Harkness, Elaine F; Smith, Miriam J.
Afiliación
  • Evans DG; Department of Genomic Medicine, St Mary's Hospital, Manchester Academic Health Sciences Centre (MAHSC), Division of Evolution and Genomic Science, University of Manchester, Manchester, UK gareth.d.evans@manchester.ac.uk.
  • Bowers NL; Department of Genomic Medicine, St Mary's Hospital, Manchester Academic Health Sciences Centre (MAHSC), Division of Evolution and Genomic Science, University of Manchester, Manchester, UK.
  • Tobi S; Department of Genomic Medicine, St Mary's Hospital, Manchester Academic Health Sciences Centre (MAHSC), Division of Evolution and Genomic Science, University of Manchester, Manchester, UK.
  • Hartley C; Department of Genomic Medicine, St Mary's Hospital, Manchester Academic Health Sciences Centre (MAHSC), Division of Evolution and Genomic Science, University of Manchester, Manchester, UK.
  • Wallace AJ; Department of Genomic Medicine, St Mary's Hospital, Manchester Academic Health Sciences Centre (MAHSC), Division of Evolution and Genomic Science, University of Manchester, Manchester, UK.
  • King AT; Department of Neurosurgery and Neuroradiology Manchester Centre for Clinical Neurosciences, Salford Royal NHS Foundation Trust, Manchester Academic Health Sciences Centre (MAHSC), Manchester, UK.
  • Lloyd SKW; Department of Otolaryngology, Manchester Royal Infirmary, Manchester Academic Health Sciences Centre (MAHSC), University of Manchester, Manchester, UK.
  • Rutherford SA; Department of Neurosurgery and Neuroradiology Manchester Centre for Clinical Neurosciences, Salford Royal NHS Foundation Trust, Manchester Academic Health Sciences Centre (MAHSC), Manchester, UK.
  • Hammerbeck-Ward C; Department of Neurosurgery and Neuroradiology Manchester Centre for Clinical Neurosciences, Salford Royal NHS Foundation Trust, Manchester Academic Health Sciences Centre (MAHSC), Manchester, UK.
  • Pathmanaban ON; Department of Neurosurgery and Neuroradiology Manchester Centre for Clinical Neurosciences, Salford Royal NHS Foundation Trust, Manchester Academic Health Sciences Centre (MAHSC), Manchester, UK.
  • Freeman SR; Department of Otolaryngology, Manchester Royal Infirmary, Manchester Academic Health Sciences Centre (MAHSC), University of Manchester, Manchester, UK.
  • Ealing J; Department of Neurology, Salford Royal Foundation Trust, Manchester Academic Health Sciences Centre (MAHSC), Manchester, UK.
  • Kellett M; Department of Neurology, Salford Royal Foundation Trust, Manchester Academic Health Sciences Centre (MAHSC), Manchester, UK.
  • Laitt R; Department of Neurosurgery and Neuroradiology Manchester Centre for Clinical Neurosciences, Salford Royal NHS Foundation Trust, Manchester Academic Health Sciences Centre (MAHSC), Manchester, UK.
  • Thomas O; Department of Neurosurgery and Neuroradiology Manchester Centre for Clinical Neurosciences, Salford Royal NHS Foundation Trust, Manchester Academic Health Sciences Centre (MAHSC), Manchester, UK.
  • Halliday D; Oxford Centre for Genomic Medicine, Nuffield Orthopaedic Centre, Oxford University Hospitals NHS Trust, Oxford, UK.
  • Ferner R; Department of Neurology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Taylor A; Department of Medical Genetics, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Duff C; Department of Plastic Surgery, Wythenshawe Hospital, Manchester Universities Foundation Trust, Manchester Academic Health Sciences Centre (MAHSC), Manchester, UK.
  • Harkness EF; Division of Informatics, Imaging and Data Sciences, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
  • Smith MJ; Department of Genomic Medicine, St Mary's Hospital, Manchester Academic Health Sciences Centre (MAHSC), Division of Evolution and Genomic Science, University of Manchester, Manchester, UK.
J Neurol Neurosurg Psychiatry ; 89(11): 1215-1219, 2018 11.
Article en En | MEDLINE | ID: mdl-29909380
OBJECTIVES: Schwannomatosis is a dominantly inherited condition predisposing to schwannomas of mainly spinal and peripheral nerves with some diagnostic overlap with neurofibromatosis-2 (NF2), but the underlying epidemiology is poorly understood. We present the birth incidence and prevalence allowing for overlap with NF2. METHODS: Schwannomatosis and NF2 cases were ascertained from the Manchester region of England (population=4.8 million) and from across the UK. Point prevalence and birth incidence were calculated from regional birth statistics. Genetic analysis was also performed on NF2, LZTR1 and SMARCB1 on blood and tumour DNA samples when available. RESULTS: Regional prevalence for schwannomatosis and NF2 were 1 in 126 315 and 50 500, respectively, with calculated birth incidences of 1 in 68 956 and 1 in 27 956. Mosaic NF2 causes a substantial overlap with schwannomatosis resulting in the misdiagnosis of at least 9% of schwannomatosis cases. LZTR1-associated schwannomatosis also causes a small number of cases that are misdiagnosed with NF2 (1%-2%), due to the occurrence of a unilateral vestibular schwannoma. Patients with schwannomatosis had lower numbers of non-vestibular cranial schwannomas, but more peripheral and spinal nerve schwannomas with pain as a predominant presenting symptom. Life expectancy was significantly better in schwannomatosis (mean age at death 76.9) compared with NF2 (mean age at death 66.2; p=0.004). CONCLUSIONS: Within the highly ascertained North-West England population, schwannomatosis has less than half the birth incidence and prevalence of NF2.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Factores de Transcripción / Neurofibromatosis / Neurofibromina 2 / Proteína SMARCB1 / Neurilemoma Tipo de estudio: Incidence_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: J Neurol Neurosurg Psychiatry Año: 2018 Tipo del documento: Article Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Factores de Transcripción / Neurofibromatosis / Neurofibromina 2 / Proteína SMARCB1 / Neurilemoma Tipo de estudio: Incidence_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: J Neurol Neurosurg Psychiatry Año: 2018 Tipo del documento: Article Pais de publicación: Reino Unido